Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

Authors

GRELL Peter FABIAN Pavel KHOYLOU M RADOVÁ Lenka SLABÝ Ondřej HRSTKA Roman VYZULA Rostislav HAJDÚCH Marian SVOBODA Marek

Year of publication 2012
Type Article in Periodical
Magazine / Source International Journal of Oncology
Citation
Doi http://dx.doi.org/10.3892/ijo.2012.1576
Field Oncology and hematology
Keywords breast cancer; HER2 protein; trastuzumab; AKT1 protein; AKT2 protein; prognosis
Description Trastuzumab is effective in about half of HER2- positive breast cancer patients. The PI3K/Akt signalling pathway plays an important role in the process of primary and secondary resistance to anti-HER2 targeted therapy. We evaluated the relationship between expression, activation and subcellular localization of selected Akt isoforms and response to trastuzumab-based anti-HER2 targeted therapy in patients with HER2-positive metastatic breast cancer.

You are running an old browser version. We recommend updating your browser to its latest version.

More info